| Literature DB >> 34943648 |
Guillem Navarro1,2, Luis Lozano2,3, Sergi Sastre2,3, Rosa Bori2, Jordi Bosch4, Guillem Bori2,3,5.
Abstract
The objective of this study was to evaluate our preliminary results after changing our surgical strategy from 2-stage revision arthroplasty to 1-stage revision arthroplasty for patients with chronic knee periprosthetic joint infection. We conducted a prospective study of knee arthroplasty patients that had been diagnosed with chronic infection and treated using a 1-stage revision regardless of the traditional criteria applied for indication thereof. We evaluated two main variables: infection control and economic costs. The definitive diagnosis of infection of the revision was determined by using the criteria proposed by the Musculoskeletal Infection Society. The costs were calculated as average costs in USD, as described by Srivastava (2019), for 1-stage or 2-stage revisions. Eighteen patients were included in the study, and infection was controlled in 17 patients. The total economic savings for our hospital from these 18 patients amounted to USD 291,152. This clinical success has led to major changes in how our hospital approaches the treatment of chronically infected knee replacements, in addition to substantial economic advantages for the hospital.Entities:
Keywords: 1-stage arthroplasty; knee arthroplasty; knee infection; single-stage revision
Year: 2021 PMID: 34943648 PMCID: PMC8698198 DOI: 10.3390/antibiotics10121436
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Patients included and excluded in the study.
|
|
Characteristics of patients and preoperative findings.
| N | Age/Gender/ASA | Comorbidities | Primary | Age of the Prosthesis (Years) | CRP/ESR | Signs of | Bone | Leukocyte Scintigraphy | Arthrocentesis | Arthrocentesis | Previous | Previous Type of Antibiotic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 84/W/II | 0 | Osteoarthritis | 0.9 | 2.19/74 | Yes/Yes | NP | NP | NP/NP |
| Yes | Cotrimozazole c |
| 2 | 75/W/III | 3 | Osteoarthritis | 4 | 0.33/3 | Yes/No | NP | NP | NP/NP |
| No | - |
| 3 | 67/M/II | 1 | Osteoarthritis | 14 | 2.2/2 | Yes/Yes | NP | NP | NP/NP | Yes | Levofloxacin + Minociclyn d | |
| 4 | 62/W/III | 4,5,6 | Osteoarthritis | 1.7 | 4.9/24 | Yes/No | NP | NP | 34.860/95 |
| No | - |
| 5 | 72/W/II | 1 | Osteoarthritis | 5 | 8.06/107 | Yes/No | Loosening | Infection | 37.400/90 |
| Yes | Amoxicillin |
| 6 | 71/W/II | 1 | Osteoarthritis | 9 | 11.79/131 | Yes/No | Loosening | NP | NP/NP |
| Yes | Amoxicillin |
| 7 | 81/W/II | 1 | Osteoarthritis | 4 | 3.3/92 | Yes/No | NP | NP | NP/NP |
| No | - |
| 8 | 81/M/II | 1 | Osteoarthritis | 0.9 | 8.48/100 | Yes/No | NP | NP | 57.880/96 |
| Yes | Ceftriaxone |
| 9 | 69/M/II | 1,4 | Osteoarthritis | 1.5 | 2.23/5 | Yes/Yes | Loosening | Infection | NP/NP |
| No | - |
| 10 | 84/W/III | 1,2,3 | Osteoarthritis | 3 | 14.1/41 | Yes/No | NP | NP | NP/98 |
| Yes | Amoxicillin/clavulanic |
| 11 | 68/W/I | 0 | Osteoarthritis | 2 | 3.91/126 | Yes/No | NP | NP | 23.360/87 |
| Yes | Amoxicillin |
| 12 | 82/W/II | 0 | Osteoarthritis | 5 | 1.54/43 | Yes/No | Loosening | Infection | NP/NP |
| No | - |
| 13 | 78/W/III | 1,3,4 | Osteoarthritis | 0.8 | 15/140 | Yes a/No | NP | NP | 50/NP |
| No | - |
| 14 | 79/W/II | 1,3,4 | Osteoarthritis | 9 | 0.26/13 | Yes/No | NP | NP | 190/NP |
| Yes | Amoxicillin |
| 15 | 87/W/III | 1,2,3 | Osteoarthritis | 11 | 4.96/82 | Yes/No | NP | NP | 900/90 |
| Yes | Ciprofloxacin |
| 16 | 82/W/III | 1,2,3 | Osteoarthritis | 3 | 7.52/59 | Yes/No | Loosening | NP | 26.750/90 |
| Yes | Levofloxacin + Minociclyn |
| 17 | 93/M/III | 1,7 | Osteoarthritis | 3 | 16.2/- | Yes/No | NP | NP | 950/NP |
| Yes | Daptomycin + Ceftriaxone |
| 18 | 69/M/II | 1,2,3 | Osteoarthritis | 4 | 0.28/5 | No/No | Loosening | Infection | 740/28 | Negative | No |
|
N: number of patients; Comorbidities: 1: High blood pressure, 2: Chronic anticoagulation, 3: Heart diseases, 4: Diabetes mellitus, 5: Hepatopathy, 6: Chronic obstructive pulmonary disease, 7: Chronic kidney disease; Gender: W: women, M: men; CRP: C-reactive protein (mg/dL), ESR: erythrocyte sedimentation rate (mm/h); WBC: white blood cell; NP: not performed; a Infected femur pseudoarthrosis + loosening knee arthroplasty; b From sinus tract; c Cotrimoxazole 2 months before + (Linezolid + Cotrimoxazole) 3 weeks before + (Meropenem + Daptomycin) 2 days before; d (Levofloxacin + Minociclyn) one week a month.
Intraoperative findings, antibiotic therapy, complications, and outcomes.
| N | Histology | L | Sm | Sc | Microorganism | ArthrocentesisSynovial | Intravenous Prolonged Prophylaxis Antibiotic (5–10 days) | Cement | Complications | Follow-Up (Months/Last CRP/Cured or not Cured) | Knee Society Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Positive | 0/2 | 0/2 | 0/2 | Negative | 850/83 | Meropenem + Daptomycin | G/Tmx + R/42 | No | 61/<0.4/Cured | 57–30/94–40 |
| 2 | Negative | 0/2 | 0/2 | 0/2 | Negative | 50/NP | Meropenem + Linezolid | G + V/Lin/42 | Instability d | 55/<0.4/Cured | 66–50/50–0 k |
| 3 | Positive | 0/2 | 0/2 | 0/2 | Negative a | NP/NP | Meropenem + Linezolid | G/Lin + Amox/42 | No | 52/<0.4/Cured | 63–50/94–80 |
| 4 | Negative | 2/2 | 0/2 | 0/2 |
| NP/94 | Meropenem + Cloxacillin | G/Le + R/42 | No | 50/<0.4/Cured | 57–25/69–10 |
| 5 | Negative | 0/2 | 0/2 | 0/2 | Negative | 37,580/94 | Meropenem + Linezolid | G/Amox + R/42 | Dislocation at 9 weeks e | 49/<0.4/Cured | 53–15/94–45 |
| 6 | Negative | 0/2 | 0/2 | 0/2 | Negative b | 24,830/91 | Meropenem + Linezolid | G/Amox + R/42 | No | 48/<0.4/Cured | 53–50/94–80 |
| 7 | Positive | 2/2 | 0/2 | 0/2 |
| 31,200/97 | Meropenem + Linezolid | G + V/Lin/42 | No | 47/0.8/Cured | 55–50/64–55 |
| 8 | Negative | 0/2 | 0/2 | 0/2 | Negative | 21,120/86 | Meropenem + Linezolid + Cipro | G/Ci/42 | No | 45/<0.4/Cured (Death) | −/94–55 |
| 9 | Positive | 2/2 | 0/2 | 1/2 |
| NP/NP | Meropenem + Linezolid | G/Lin + Ci/42 | Acute infection at 1 month/stiffness 0–45° f | 44/0.7/Cured | 28–5/51–25 |
| 10 | Positive | 0/2 | 0/2 | 0/2 | Negative | NP/NP | Meropenem + Linezolid | G/Moxi/42 | No | 42/2.5 j/Cured | 53–5/96–80 |
| 11 | Positive | 0/2 | 0/2 | 0/2 | Negative | 25,000/89 | Meropenem + Linezolid | G/Amox + R/42 | No | 42/0.8/Cured | 43–60/95–100 |
| 12 | Negative | 0/2 | 0/2 | 0/2 | Negative | NP/NP | Meropenem + Linezolid | G/Le + R/42 | No | 41/1.6/Cured | 51–0/88–60 |
| 13 | Negative | 0/2 | 0/2 | 0/2 | Negative | 190/NP | Meropenem + Linezolid | G/Le + R/42 | Quadricipital tendon rupture at 2 months/relapse at 26 months g | 26/–/Failure | 44–0/– |
| 14 | Negative | 0/2 | 0/2 | 0/2 | Negative | 1280/NP | Meropenem + Linezolid | G/Le + R/42 | No | 39/<0.4/Cured | 53–30/89–60 |
| 15 | Positive | 0/2 | 0/2 | 0/2 | Negative | NP/95 | Meropenem + Linezolid | G/Ci/42 | No | 38/<0.4/Cured | 43–0/94–60 |
| 16 | Positive | 0/2 | 0/2 | 0/2 | Negative | NP/NP | Meropenem + Linezolid | G/Le + R/42 | No | 36/<0.4/Cured | 55–0/94–15 |
| 17 | Negative | 0/2 | 0/2 | 0/2 | Negative | 12,800/79 | Meropenem + Linezolid | G/Amox + R/42 | Periprosthetic fracture at 29 months h | 37/<0.4/Cured | −/88–50 |
| 18 | Negative | 0/2 | 1/2 | 1/2 |
| NP/51 | Meropenem + Linezolid | G/Dal/42 | Neuroma of infrapatellar branch of saphenous nerve i | 37/0.48/Cured | 65–30/74–70 |
N: Number of patients; Histology: Positive: ≥5 neutrophils per high-power field (400×), Negative: <5 neutrophils per high-power field (400×), NP: Not performed; L: liquid samples inoculated in blood culture flasks, S: solid samples; Sw: swab samples; a Propionibacterium acnes in sonication; b Streptococcus vestibularis in sonication; c Staphylococcus epidermidis in sonication also; d The patient needed to change the polyethylene 8 months later; e The patient needed a closed reduction f The patient needed an irrigation and debridement g The patient needed a tendon repair. Irrigation and debridement plus suppressive antibiotic treatment;h Orthopedic treatment with plaster was used; i Pain due to the infrapatellar branch of saphenous nerve. Excision of the neuroma was performed 14 months later; j Polymyalgia rheumatic; k Multiple vertebral fractures; CRP: C-reactive protein (mg/dL); Antibiotic-loaded cement: G: gentamicin, V: vancomycin; Oral Antibiotics: Le: levofloxacin, R: rifampicin, Lin: linezolid. Ci: ciprofloxacin, Amox: amoxicillin; Tmx: trimetropim–sulfamethoxazole, Moxi: moxifloxacin, Dal: dalbavancin.
Infection control and Knee Society Score (KSS) results.
| Infection Control | Scores | Preoperative Results | Postoperative Results | ||
|---|---|---|---|---|---|
| Knee Score | Functional Score | Knee Score | Functional Score | ||
| Cure | Excellent | - | - | 11 | 4 |
| Good | - | - | 1 | 1 | |
| Fair | 3 | 1 | 3 | 3 | |
| Poor | 12 | 14 | 2 | 9 | |
| Failure | Excellent | - | - | - | - |
| Good | - | - | - | - | |
| Fair | - | - | - | - | |
| Poor | 1 | 1 | - | - | |
Scores; Excellent: 100–80, Good: 70–79, Fair: 60–69, Poor: <60.
Figure 1Preoperative X-ray of knee joint with Streptococcus anginosus infection of patient number 5.
Figure 2Postoperative X-ray of new knee prosthesis of patient number 5.